eIF3M inhibitors are a class of chemical compounds that specifically target and inhibit the activity of the eukaryotic translation initiation factor 3 subunit M (eIF3M). eIF3M is a component of the eIF3 complex, which is a crucial player in the initiation phase of eukaryotic translation. The eIF3 complex is the largest and most complex of the translation initiation factors, composed of multiple subunits, including eIF3M. This complex plays a critical role in the recruitment of the small ribosomal subunit to the mRNA, the scanning of the mRNA for the start codon, and the assembly of the translation machinery. Inhibiting eIF3M can disrupt the overall function of the eIF3 complex, thereby impeding the translation initiation process. This makes eIF3M inhibitors important tools in research for studying the specific role of this subunit in translation and its broader impact on protein synthesis.
The study of eIF3M inhibitors provides valuable insights into the mechanistic aspects of translation initiation. By selectively inhibiting eIF3M, researchers can dissect the specific contributions of this subunit to the eIF3 complex's function and its interaction with other components of the translation machinery. This approach allows scientists to explore how eIF3M influences the regulation of gene expression at the translational level, as well as its involvement in various cellular processes that depend on efficient protein synthesis. Furthermore, eIF3M inhibitors can help identify potential regulatory networks that modulate the activity of the eIF3 complex, offering a deeper understanding of how cells control protein production under different physiological conditions. Overall, eIF3M inhibitors are essential tools for advancing our knowledge of translation initiation and the complex molecular mechanisms that govern this fundamental process in eukaryotic cells.
SEE ALSO...
Items 1 to 10 of 14 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Salubrinal | 405060-95-9 | sc-202332 sc-202332A | 1 mg 5 mg | $34.00 $104.00 | 87 | |
Salubrinal inhibits eIF2α dephosphorylation, leading to prolonged phosphorylation, which reduces translation initiation. | ||||||
Guanabenz HCl | 23113-43-1 | sc-507500 | 100 mg | $246.00 | ||
Guanabenz reduces eIF2α phosphorylation by activating the eIF2α phosphatase, PP1, allowing translation to proceed normally. | ||||||
GSK 2606414 | 1337531-36-8 | sc-490182 sc-490182A | 5 mg 25 mg | $163.00 $572.00 | ||
GSK2606414 inhibits the activity of PERK, a kinase that phosphorylates eIF2α, reducing eIF2α phosphorylation levels. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
Cisplatin indirectly affects eIF2α by causing DNA damage, triggering the integrated stress response and eIF2α phosphorylation. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin induces ER stress, activating PERK and leading to eIF2α phosphorylation, thereby inhibiting protein synthesis. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide causes DNA damage, which could lead to a cellular stress response, potentially diverting cellular resources from RNAi pathways and thus down-regulating eIF2C2. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, affecting protein turnover. This can disrupt the balance of cellular proteins, potentially decreasing the stability or synthesis of eIF2C2. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D hinders RNA synthesis by intercalating DNA. This can lead to a general down-regulation of RNA-derived processes, which might include a decrease in eIF2C2 levels. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
By inhibiting protein synthesis, Cycloheximide might halt the production of new eIF2C2 molecules, leading to a net decrease in eIF2C2 as existing proteins degrade. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
DNA damage from Doxorubicin may cause the cell to prioritize DNA repair over regular functions, potentially suppressing RNAi machinery and decreasing eIF2C2 levels. | ||||||